The test could potentially deliver noninvasive results in less than one minute through analysis of exhaled volatile organic compounds.

The test helps diagnose infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.

Uniogen's progress toward clinical commercialization aligns with larger internal goals of bringing cancer diagnostics to market, with a specific focus on women's health.

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.

Last week, readers were most interested in a story about FDA approving Cleveland Diagnostics' prostate cancer test.

The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.

Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.